Factor VIII (F8) Mouse Monoclonal Antibody [Clone ID: 2A5]

Specifications

Product Data
Clone Name	2A5
Applications	ELISA
Recommend Dilution	ELISA.
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Immunogen	Purified Human Factor VIII
Specificity	This antibody recognizes the 83 kDa light chain of Factor VIII. It does not cross-react with Von Willebrand factor.
Formulation	PBS, pH 7.2 containing 0.09% Sodium Azide as preservative State: Purified State: Liquid purified IgG fraction
Concentration	lot specific
Purification	Affinity Chromatography on Protein A
Conjugation	Unconjugated
Storage Condition	Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing.
Gene Name	coagulation factor VIII
Database Link	Entrez Gene 2157 Human UniProt ID P00451
Background	Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50% of patients have severe hemophilia A with F8C activity less than 1% of normal; they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10% of patients; F8C activity is 2-5% of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40% of patients, is associated with F8C activity of 5-30% and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8C in their plasma (at least 30% of normal), but the protein is nonfunctional; i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.
Synonyms	Procoagulant component, Antihemophilic factor, F8C, AHF
Reference Data

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.